Sort
10,766 grants matching “checkpoint inhibitor”
Advanced therapeutic for Parkinson's Disease
$1,554,108Milton H. Werner · Inhibikase Therapeutics · R44 · FY2019 · NS
Advanced therapeutic for Parkinson's Disease
$1,554,020Milton H. Werner · Inhibikase Therapeutics · R44 · FY2017 · NS
Cellular Interactions with Thrombospondin
$1,551,374David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2020 · CA
Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies
$1,548,129Anish Thomas · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Advanced therapeutic for Parkinson's Disease
$1,546,730Milton H. Werner · Inhibikase Therapeutics · R44 · FY2020 · NS
Pathway inhibitors in Lymphomas
$1,541,889Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Preclinical drug development in pancreatic cancer
$1,539,190Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies
$1,537,766William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2022 · CA
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$1,535,915Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Yale SPORE in Skin Cancer
$1,533,274Marcus W Bosenberg · Yale University · P50 · FY2023 · CA
Mechanisms Of Genome Instability
$1,530,020Michael A Resnick · National Institute Of Environmental Health Sciences · ZIA · FY2012 · ES
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$1,528,231Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$1,528,231Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Expanding CAR T cell applications through high-throughput forward- and reverse immune engineering
$1,525,500Mark Yarmarkovich · New York University School Of Medicine · DP2 · FY2024 · CA
Targetable epigenetic and transcriptional mechanisms in melanoma that shape the microenvironment
$1,516,688David E Fisher · Massachusetts General Hospital · P01 · FY2019 · CA
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer
$1,516,118Angelo Michael De Marzo · Johns Hopkins University · U54 · FY2025 · CA
Cancer Immunotherapy Clinical Trials
$1,516,058Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Human Translational Studies of Vascular Thrombosis and Inflammation
$1,516,044Yogendra Kanthi · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
Clinical and Mechanistic Investigations of Salivary Gland Dysfunction
$1,512,283Blake Warner · National Institute Of Dental & Craniofacial Research · ZIA · FY2023 · DE
Characterization and Enhancement of Anti-Tumor Immune Responses in Head and Neck Cancer
$1,510,517Clint Allen · National Institute On Deafness And Other Communication Disorders · ZIA · FY2017 · DC
Therapy for NF1-Related Tumors and other Genetic Tumor Predisposition Syndromes
$1,507,659Brigitte Widemann · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Immunotherapy for Malignant Mesothelioma, Lung Cancer and Thymic Malignancies
$1,506,569Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Cancer immunotherapy
$1,503,964Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiency
$1,500,000Brad H. Pollock · Public Health Institute · UG1 · FY2022 · CA
Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity
$1,499,996Nicolas Palaskas · University Of Tx Md Anderson Can Ctr · U01 · FY2025 · FD